

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Eligibility

Effective December 20, 2021

Certain eligible pharmacies can administer publicly funded injectable COVID-19 vaccines to eligible Ontarians (see Pharmacy Eligibility below).

The purpose of this Executive Officer (EO) Notice (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**), the EO Notice: Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Billing**, and the accompanying Questions and Answers (Qs & As) documents, are to set out the terms and conditions for a participating pharmacy's submission of claims for payment (claims) for administering injectable COVID-19 vaccines to eligible Ontarians. Each document is a ministry policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators. Participating pharmacies must comply with all of the terms and conditions set out in the EO Notices and Qs & As. It is a condition of participating that participating pharmacies offer first, second and third or booster doses to all eligible groups, provided that there is sufficient supply of the vaccines.

The two (2) EO Notices and the accompanying Qs & As documents are **not** intended to describe a pharmacy operator's obligations in respect of administering injectable COVID-19 vaccines under applicable legislation, other agreements with the Province of Ontario, or policies of the OCP. Pharmacy operators with questions about their legal obligations outside of the HNS Subscription Agreement should refer to the applicable legislation, other agreement, or OCP policy as appropriate.

This EO Notice (Administration of the Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – **Eligibility**) replaces the previous EO notice on the same topic respecting the administration of publicly funded COVID-19 vaccines in Ontario pharmacies that was effective December 17th, 2021.

Pharmacy eligibility

In order to be eligible to submit claims for administering a publicly funded COVID-19 vaccine, a pharmacy operator (also referred to in this document as a “participating pharmacy”) must be selected to participate by the ministry and meet the following requirements:

- Have a valid HNS Subscription Agreement with the ministry
- Have a valid agreement with the ministry respecting COVID-19 vaccine administration and the use of the Provincial COVID-19 vaccine solution (the “COVID-19 Vaccine Agreement”); and
- Enrolled in the 2021-22 Universal Influenza Immunization Program (UIIP).

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice.

Patient eligibility

The following rules apply to the interpretation of the eligibility criteria in **Tables 1, 2, 3 and 4** below for any vaccine dose.

An individual is eligible to receive a publicly funded COVID-19 vaccine if they live, work, or study in Ontario or they are here for an extended stay, and if they meet the applicable eligibility criteria in the tables below.

Individuals who received a COVID-19 vaccine outside of Ontario or Canada who contact their local Public Health Unit will have their COVID-19 vaccine history verified and uploaded into the COVAX system. Depending on how many doses and which vaccines were previously administered (please refer to the [COVID-19 Guidance for Individuals Vaccinated outside of Ontario/Canada](#) located on the [ministry’s website](#)), pharmacies may administer an additional dose of an mRNA vaccine if required to complete the vaccine series, in alignment with the ministry’s guidance “[Who is considered to be fully vaccinated in Ontario](#)”.

Informed consent is required to administer any COVID-19 vaccine to an eligible individual.

Ontario recommends mRNA vaccines as the preferred vaccine for all Ontarians. However, individuals 18 and older can request a viral vector vaccine (Janssen or AstraZeneca / COVISHIELD vaccine) if a mRNA vaccine is declined and after informed consent. Individuals who have contraindications such as a confirmed allergy to components of the

mRNA vaccines may also receive a viral vector vaccine. The Province has a limited supply of viral vector vaccines. Pharmacies should work with their public health unit to determine how eligible individuals (as defined below) can receive these vaccines.

Based on advice from Ontario’s Vaccine Clinical Advisory Group, and in alignment with [NACI](#), the Ministry of Health has issued a **preferential recommendation for the use of Pfizer-BioNTech COVID-19 vaccine for individuals 12-29 (including those turning 12 in 2021)**. This recommendation stems from an observed increase in the number of reports in Ontario of myocarditis/pericarditis following vaccination with Moderna relative to Pfizer-BioNTech in the 18-29 year old age group, particularly among males. See [Vaccination Recommendations for Special Populations for more details](#).

Residents of long-term care homes, residents of retirement homes, and elderly persons living in other congregate settings (e.g. assisted-living facilities, naturally occurring congregate retirement settings/seniors apartment buildings, congregate settings for people with developmental disabilities, mental health and addictions issues, etc.) who meet the eligibility criteria in the tables below are only eligible to receive a pharmacy-administered vaccine dose when pharmacy staff administer the dose at the long-term care home, retirement home or other congregate setting. Staff, support workers, essential caregivers, volunteers and contractors who are working at the long-term home, retirement home or other congregate settings are also eligible for pharmacy-administered vaccine doses either at the pharmacy or when the pharmacy staff visit the home / congregate setting, provided that they meet the applicable eligibility criteria in the tables below. Pharmacies must coordinate any vaccine administration at a long-term care home, retirement home or congregate setting with the local public health unit and the proprietor of the home/setting.

Individuals attending Pharmacy Mobile Clinics are subject to the eligibility requirements set out below where applicable. For more information refer to Pharmacy Qs+As Question 48.

Table 1 – Eligibility for first* or single dose administration**

Vaccine Product
<ul style="list-style-type: none"> • Pediatric Pfizer-BioNTech COVID-19 vaccine (DIN 02522454)
Eligibility Criteria for First or Single Dose Administration
<ul style="list-style-type: none"> • Children who are 5 to 11 years of age at the time of the vaccination and individuals turning 5 years of age any time during 2021.***
Vaccine Product
<ul style="list-style-type: none"> • Pfizer-BioNTech COVID-19 (12+ formulation) vaccine (DIN: 02509210); • COVID-19 vaccine MODERNA (DIN: 02510014)
Eligibility Criteria for First or Single Dose Administration
<ul style="list-style-type: none"> • Individuals who are 12 years of age or older at the time of vaccination***

Note the preferential recommendation for the use of the Pfizer (12+ formulation) vaccine in those aged 12 to 29.

Vaccine Product

- COVISHIELD COVID-19 vaccine (DIN: 02512947)
- COVID-19 vaccine AstraZeneca (PIN: 09857655)
- Janssen COVID-19 VACCINE (DIN 02513153)

Eligibility Criteria for First or Single Dose Administration

Individuals who are 18 years of age or older at the time of vaccination and who:

- have contraindications such as a confirmed allergy to components of the mRNA vaccines, if the individual has been assessed by an allergist / immunologist and the pharmacy has received a completed [COVID-19 Vaccination: Allergy Form](#) prior to administering the AstraZeneca / COVISHIELD / Janssen vaccine; or
- have requested a viral vector vaccine.

Note: at this time the Province has a limited supply of AstraZeneca / COVISHIELD and Janssen vaccines. Pharmacies should work with their public health unit to determine how eligible individuals (as defined above) can receive these vaccines.

Table 2 – Eligibility for second dose administration**

The following rules apply to the interpretation of the eligibility criteria in Table 2 below.

Persons who received a first dose of the AstraZeneca/COVISHIELD vaccine (a viral vector vaccine) should usually receive an mRNA vaccine (Pfizer-BioNTech (12+ formulation) or Moderna) for their second dose, unless contraindicated. People who experienced a severe immediate allergic reaction after a first dose of an mRNA COVID-19 vaccine can safely receive future doses of the same or another mRNA COVID-19 vaccine after consulting with an allergist/immunologist or another appropriate physician. See [NACI’s recommendations on the use of COVID-19 vaccines](#) for more information (see Table 2 below). According to the National Advisory Committee on Immunization ([NACI](#)) recommendations, an mRNA vaccine is now preferred as the second dose for individuals who received a first dose of the AstraZeneca/COVISHIELD vaccine, based on emerging evidence of a potentially better immune response from this mixed vaccine schedule and to mitigate the potential risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) associated with viral vector vaccines.

Persons who received a first dose of an mRNA vaccine (Pfizer-BioNTech (12+ formulation) or Moderna) should be offered the same mRNA vaccine for their second dose, unless the same mRNA vaccine is not readily available* or the vaccine used for the first dose is unknown, in which case, another mRNA vaccine can be considered interchangeable and should be offered to complete the vaccine series. Note: An mRNA vaccine followed by a second AstraZeneca vaccine is not an acceptable interchangeable vaccine series unless

the individual has a contraindication to the mRNA vaccines. * Note, readily available means easily available at the time of vaccination without delay or vaccine wastage.

Persons who received an mRNA vaccine for their first dose should receive their second dose 8 weeks after the first dose. Persons who received the AstraZeneca /COVISHIELD vaccine for their first dose should receive their second dose at least 8 after the first dose. There is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness. See [NACI's statement](#) for more information. Ontario strongly recommends patients wait 8 weeks after receiving their first dose before getting a second dose. However, individuals can receive their second dose earlier than 8 weeks if required, with informed consent. The appropriate minimum dose interval should be determined from the product monograph of the vaccine used for the first dose.

For more information refer to the Q&A for Health Care Providers on Mixed COVID-19 mRNA Vaccine Schedules available [here](#), and the COVID-19 Vaccine Administration Guidance available [here](#).

Children who are 11 years of age and received the Pfizer-BioNTech (12+ formulation) vaccine (30mcg dose) as their first dose under Ontario’s extended eligibility (2009 birth year, now no longer in place^{***}) are recommended to complete the vaccine series with the product authorized for their age at the time of the second dose (i.e. Pfizer-BioNTech pediatric formulation of 10mcg if 11 years old; Pfizer 12+ formulation of 30mcg if 12 years old).

Table 2 – Eligibility for second dose administration**
(please review preamble to Table 2)

Vaccine Product
<ul style="list-style-type: none"> • Pediatric Pfizer-BioNTech COVID-19 vaccine (DIN 02522454)
Eligibility Criteria for Second Dose Administration
<p>Children who are 5 to 11 years old who received their first dose with the Pfizer vaccine may receive their second dose with the Pediatric Pfizer vaccine if:</p> <ul style="list-style-type: none"> • 8 weeks have passed since their first dose with the Pfizer vaccine; or • less than 8 weeks have passed since their first dose, provided that the interval between doses is consistent with the product monograph of the vaccine used for the individual’s first dose and the individual or their substitute decision maker has provided informed consent to a shorter interval.
Vaccine Product
<ul style="list-style-type: none"> • Pfizer-BioNTech COVID-19 (12+ formulation) vaccine (DIN: 02509210); • COVID-19 vaccine MODERNA (DIN: 02510014)

Eligibility Criteria for Second Dose Administration

Individuals who received their first dose of AstraZeneca/COVISHIELD vaccine may receive one of the mRNA vaccines (Pfizer (12+ formulation) or Moderna) as their second dose if:

- at least 8 weeks have passed since their first dose; or
- less than 8 weeks have passed since their first dose, provided that the interval between doses is consistent with the product monograph of the vaccine used for the individual’s first dose and the individual or their substitute decision maker has provided informed consent to a shorter interval.

Individuals who received their first dose of an mRNA vaccine (Pfizer or Moderna) may receive one of the mRNA vaccines (Pfizer (12+ formulation) or Moderna) as their second dose if:

- 8 weeks have passed since their first dose; or
- less than 8 weeks have passed since their first dose, provided that the interval between doses is consistent with the product monograph of the vaccine used for the individual’s first dose and the individual or their substitute decision maker has provided informed consent to a shorter interval.

Vaccine Product

- COVISHIELD COVID-19 vaccine (DIN: 02512947)
- COVID-19 vaccine AstraZeneca (PIN: 09857655)

Eligibility Criteria for Second Dose Administration

Individuals who are at least 18 years old and who have contraindications such as a confirmed allergy to components of the mRNA vaccines OR who received the Pfizer-BioNTech (12+ formulation) or Moderna mRNA vaccine for their first dose and had a severe allergic reaction or anaphylaxis to that vaccine as assessed by an allergist / immunologist / specialist and documented in a [COVID-19 Vaccination: Allergy Form](#), may receive their second dose with a viral vector vaccine (for example, AstraZeneca / COVISHIELD vaccine) if recommended and if:

- 8 weeks have passed since their first dose with the Pfizer-BioNTech vaccine or the Moderna vaccine;
- at least 8 weeks have passed since their first dose with the AstraZeneca / COVISHIELD vaccine; or
- less than 8 weeks have passed since their first dose, provided that the interval between doses is consistent with the product monograph of the vaccine used for the individual’s first dose and the individual or their substitute decision maker has provided informed consent to a shorter interval.

Note: at this time the Province has a limited supply of a viral vector vaccines. Pharmacies should work with their public health unit to determine how eligible individuals (as defined above) can receive the vaccine.

Table 3 – Eligibility for third or booster dose administration**

Refer to the ministry’s [COVID-19 Vaccine Third Dose Recommendations](#) Guidance for information.

The following rules apply to the interpretation of the eligibility criteria in Table 3 below.

- The Pfizer-BioNTech and Moderna COVID-19 vaccines have been [authorized for use](#) by Health Canada as a booster dose after completion of the primary series in individuals 18 years of age and older.
- Individuals who received AstraZeneca/COVISHIELD COVID-19 vaccine for their first and second dose are recommended to receive an mRNA vaccine for their third or booster dose.
- People who experienced a severe immediate allergic reaction after a first dose of an mRNA COVID-19 vaccine can safely receive future doses of the same or another mRNA COVID-19 vaccine after consulting with an allergist/immunologist or another appropriate physician. See [NACI’s recommendations on the use of COVID-19 vaccines](#) for more information.
- If an individual needs to or chooses to receive a third or booster dose of a viral vector vaccine, informed consent should include discussion about the lack of evidence on the use of an additional dose of viral vector COVID-19 vaccine and the increased risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), Capillary Leak Syndrome (CLS), and Guillain-Barre syndrome (GBS) following viral vector COVID-19 vaccines ([NACI, 2021](#)). Only individuals who are at least 18 years old can receive a third or booster dose with a viral vector vaccine.
- At this time the Province has a limited supply of viral vector vaccines. Pharmacies should work with their public health unit to determine how eligible individuals (as defined above) can receive the vaccine.
- The Janssen COVID-19 vaccine series involves a single dose. However, individuals who received the single dose Janssen vaccine are eligible for a supplementary or booster dose in accordance with this section. References in this section to individuals who have already received two doses of a COVID-19 vaccine shall be interpreted to include individuals who received the single dose Janssen vaccine. In addition, for immunocompromised individuals who received the single dose Janssen vaccine, references in this section to a third dose shall be interpreted to mean a second dose.
- Persons who received a second dose of an mRNA vaccine (Pfizer-BioNTech (12+ formulation) or Moderna) should be offered the same mRNA vaccine for their third or booster dose, unless the same mRNA vaccine is not readily available* or the vaccine used for the second dose is unknown, in which case, another mRNA vaccine can be

considered interchangeable and should be offered. *Note, readily available means easily available at the time of vaccination without delay or vaccine wastage.

- Residents of long-term care homes, residents of retirement homes, elderly (65 years of age and older) living in other congregate living settings and immunocompromised individuals are recommended to receive the full dose of either Moderna (100 mcg) or Pfizer-BioNTech (12+ formulation or 30 mcg) for third or booster doses. ¹ Note: For children ages 5-11 who are immunocompromised, the pediatric Pfizer-BioNTech (10mcg) vaccine should be given as the third dose.
- For individuals in all other population groups noted in Table 3 who are receiving a booster dose see the following dose information:
 - Moderna: the full dose (100 mcg) is recommended for adults 70 years of age or older, while a half dose (50 mcg) is recommended for those less than 70 years of age.
 - Pfizer-BioNTech (12+ formulation): the full dose (30 mcg) is recommended for all booster doses. ²
 - Pediatric Pfizer-BioNTech: a dose of (10mcg) should be given for a **third** dose for eligible children ages 5-11 who are immunocompromised.****

Table 3 – Eligibility for third or booster dose administration**

(please review preamble to Table 3)

<p>Vaccine Product</p> <ul style="list-style-type: none"> • Pediatric Pfizer-BioNTech COVID-19 vaccine (DIN 02522454) • Pfizer-BioNTech COVID-19 (12+ formulation) vaccine (DIN: 02509210); • COVID-19 vaccine MODERNA (DIN: 02510014) • COVISHIELD COVID-19 vaccine (DIN: 02512947) • COVID-19 vaccine AstraZeneca (PIN: 09857655) • Janssen COVID-19 VACCINE (DIN 02513153)
<p>Eligibility Criteria for Third Dose Administration</p> <p>3rd Dose for Immunocompromised Individuals</p> <ul style="list-style-type: none"> • Individuals 5 years of age and older (or 18 years of age and older, in the case of viral vector vaccines) from the following moderately to severely immunocompromised population groups that present with a referral letter from their health care provider OR are taking an immunosuppressant medication listed here, if at least 2 months (56 days) have passed since receiving their second dose or at an interval of at least 28 days as directed in writing by a health care provider: <ul style="list-style-type: none"> ○ Individuals receiving dialysis (hemodialysis or peritoneal dialysis)

¹ See [NACI's recommendation](#) and ministry 3rd Dose Recommendation [Guidance](#) for more details.

² Ibid

- Individuals receiving active³ treatment (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
- Recipients of solid-organ transplant and taking immunosuppressive therapy
- Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy).
- Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
- Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome.
- Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies⁴ (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the [Canadian Immunization Guide](#) for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive.

Note: Pharmacists may verify whether a patient is eligible for a 3rd dose of a COVID-19 vaccine based on the patient’s use of an immunosuppressant medication listed [here](#) by referring to a patient’s recent prescription label or prescription receipt or their medication profile. If an individual presents a prescription of a medication that is not listed [here](#), they should be directed to their health care provider to receive a referral form/letter for a third dose of the COVID-19 vaccine.

Vaccine Product

- Pfizer-BioNTech COVID-19 (12+ formulation) vaccine (DIN: 02509210);
- COVID-19 vaccine MODERNA (DIN: 02510014)
- COVISHIELD COVID-19 vaccine (DIN: 02512947)
- COVID-19 vaccine AstraZeneca (PIN: 09857655)
- Janssen COVID-19 VACCINE (DIN 02513153)

Booster Doses for the following groups:

As of December 17, 2021:

³ Active treatment includes patients who have completed treatment within 3 months. Active treatment is defined as chemotherapy, targeted therapies, immunotherapy, and excludes individuals receiving therapy that does not suppress the immune system (e.g. solely hormonal therapy or radiation therapy). See Ontario Health/Cancer Care Ontario's [Frequently Asked Questions](#) for more information.

⁴ Active treatment for patients receiving B-cell depleting therapy includes patients who have completed treatment within 12 months

- All individuals aged 18 years and older if at least 3 months (84 days) have passed since completing a primary COVID-19 vaccine series with an mRNA or viral vector vaccine, including immunocompromised individuals who have completed a three-dose vaccine series (see above *3rd Dose for Immunocompromised Individuals*).

Table 4 – Eligibility to repeat COVID-19 vaccine series

It is recommended that a re-vaccination with a repeat COVID-19 vaccine primary series plus booster (if applicable) be initiated post-transplantation for hematopoietic stem cell transplant (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy given the loss of immunity following therapy or transplant.⁵ [Optimal timing for re-immunization](#) should be determined on a case-by-case basis in consultation with the clinical team.

Vaccine Product

- Pfizer-BioNTech COVID-19 (12+ formulation) vaccine (DIN: 02509210);
- COVID-19 vaccine MODERNA (DIN: 02510014)
- COVISHIELD COVID-19 vaccine (DIN: 02512947)
- COVID-19 vaccine AstraZeneca (PIN: 09857655)
- Janssen COVID-19 VACCINE (DIN 02513153)

Eligibility Criteria for re-vaccination series

Individuals who already received a primary COVID-19 vaccine series (plus booster dose, if applicable) and who receive hematopoietic stem cell transplants (HSCT), hematopoietic cell transplants (HCT) (autologous or allogeneic), and recipients of CAR-T-cell therapy, due to the loss of immunity following therapy or transplant.

Re-vaccination series including first, second, and third dose intervals based on a referral letter from a health care provider.

If applicable a booster dose may be administered if at least 3 months (84 days) have passed since completing re-vaccination with a complete COVID-19 vaccine series.

* See Executive Officer Notice dated May 11, 2021 regarding the Ministry of Health’s direction to pause the administration of first doses of publicly funded AstraZeneca / COVISHIELD COVID-19 vaccines in Ontario pharmacies, available [here](#).

⁵ As per the [Canadian Immunization Guideline](#), HSCT recipients should be viewed as vaccine naïve (i.e. never immunized) and require re-immunization after transplant.

**See the most recent version of the Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies – Billing for age restrictions for the vaccines based on the applicable product monographs, available [here](#).

*** Pharmacies should be informed and stay current with the vaccine's official indications in accordance with Health Canada's approved product monograph. The Pfizer-BioNTech COVID-19 vaccine (12+ formulation) is currently indicated for use in individuals 12 years of age and older. However, Ontario had previously extended eligibility for the Pfizer-BioNTech COVID-19 vaccine (12+ formulation) to all children born in 2009 to allow administration to more people at that time. This extended eligibility for the 12+ formulation is no longer in place and individuals who are 11 years old at the time of vaccination are only eligible to receive the pediatric formulation. The Pediatric Pfizer-BioNTech COVID-19 vaccine is currently indicated for use in individuals 5 to 11 years of age. However, Ontario is extending eligibility for the Pediatric Pfizer-BioNTech COVID-19 vaccine to children born in 2016.

Pharmacies should be informed and stay current with the vaccine's official indications in accordance with Health Canada's approved product monograph, including information regarding recommended dosing as per the product monograph. Ontario is funding third and booster doses for select vulnerable populations, based on recommendations of NACI, the Chief Medical Officer of Health and other health experts as noted in [ministry guidance](#) and guidance from [NACI](#).

This eligibility criteria may be updated from time to time. Please refer to the [ministry website](#) for the most recent version of this notice and for details of the provincial rollout plan, please visit the [ministry's website](#).

Prior EO Notices

- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies, effective March 10, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective March 22, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective April 1, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective April 19, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective April 30, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 6, 2021.

- Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies (May 11, 2021)
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 13, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 18, 2021.
- Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies (May 21, 2021)
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 23, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective May 31, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective June 4, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective June 14, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective June 17, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective June 25, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective July 5, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective August 18, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective September 1, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective September 8, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective October 1st, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective October 8th, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective November 3rd, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective November 25th, 2021.

- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective December 2nd, 2021.
- Executive Officer Notice: Administration of Publicly Funded COVID-19 vaccines in Ontario Pharmacies – Eligibility, effective December 17th, 2021.

Additional Information:

For pharmacy billing:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For COVID-19 vaccine rollout in pharmacy:

Please email the ministry at: OPDPInfoBox@ontario.ca

For Ministry COVID-19 Vaccine-Relevant Information and Planning Resources

Please access this [website](#)

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.